Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-15
2005-02-15
Marschel, Ardin (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S069100
Reexamination Certificate
active
06855686
ABSTRACT:
This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having the melanoma differentiation associated gene (mda-7) or the gene product of the melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5643761 (1997-07-01), Fisher
patent: 5710137 (1998-01-01), Fisher
patent: 6355622 (2002-03-01), Fisher
patent: WO9511986 (1995-05-01), None
Chen J, Chada S, Mhashilkar A, Miano JM. Mol Ther. 2003,8:220-229. Tumor suppressor MDA-7/IL-24 selectively inhibits vascular smooth muscle cell growth and migration.
Suane M, Gopalkrishnan RV, Lebedeva I, Mei MX, Sarkar D, Su ZZ, Kang DC, Dent P, Pestka S, Fisher PB. J Cell Physiol 2003,196:334-345. Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways.
Cao XX,
Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS, Fanger G, Stewart L, Watson GJ, Snary D, Fisher PB, Saeki T, Roth JA, Ramesh R, Chada S. Mol Med. 2001,7:271-282. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy.
Jiang H, Lin J, Su ZZ, Fisher PB. The melanoma differentiation associated gene-6 (mda-6), which encodes the cyclin-dependent kinase inhibitor p21, may function as a negative regulator of human melanoma growth and progression. Mol Cell Different 1996;4:67-89.
Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CSH, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996;93:9160-9165.
Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11(2):211-219.
Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995;11(12):2477-2486.
Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differntially expressed during growth, differentiation, and progression in human melanoma cells. Oncogene 1995;10(9):1855-1864.
MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5(2):127-156.
Medema RH, Herrera RE, Lam F, Weinberg RA. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995;92(14):6289-6293.
Sang N, Baldi A, Giordano A. The roles of tumor suppressors pRb and p53 in cell proliferation and cancer. Mol Cell Different 1995;3:1-29.
Shen R, Su ZZ, Olsson CA, Fisher PB. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci USA 1995;92(15):6778-6782.
Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994;54(21):5556-5560.
Falck-Pedersen E, Heinflink M, Alvira M, Nussenzveig DR, Gershengorn MC. Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. Mol Pharmacol 1994;45(4):684-689.
Jiang H, Lin J, Fisher PB. A molecular definition of terminal differentiation in human melanoma cells. Mol Cell Different 1994;2:221-239.
Lin J, Su ZZ, Grunberger D, Zimmer SG, Fisher PB. Expression of the transformed phenotype induced by diverse acting viral oncogenes mediates sensitivity to growth suppression induced by caffeic acid phenethyl ester (CAPE), Int J Oncol 1994;5:5-15.
Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211(1):90-98.
Zhan Q, Lord KA, Alamo I Jr, Hollander MC, Carrier F, Ron D, Kohn KW, Hoffman B, Liebermann DA, Fornace AJ Jr. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol 1994;14(4):2361-2371.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-825.
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
Jiang H, Fisher PB. Use of sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol Cell Different 1993;1:285-299.
Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90(23):10914-10921.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Bezjeh D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N, Harlow E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993;7(7A):1111-1125.
Boylon J, Shih T, Fisher PB, Zimmer SG. Induction and progression of the transformed phenotype in cloned rat embryo fibroblast cells: studies employing type 5 adenovirus and wild-type and mutant Ha-ras oncogenes. Mol Carcinog 1992;5:118-128.
Del Sal G, Ruaro ME, Philipson L, Schneider C. The growth arrest-specific gene, gas1, is involved in growth suppression. Cell 1992 Aug. 21;70(4):595-607.
Hara E, Yamaguchi T, Tahara H, Tsuyama N, Tsurui H, Ide T, Oda K. DNA-DNA subtractive cDNA cloning using oligo(dT)30-Latex and PCR: identification of cellular genes which are overexpressed in senescent human diploid fibroblasts. Anal Biochem 1993;214(1):58-64.
Leon JA, Gutierrez MC, Jiang H, Estabrook A, Waxman S, Fisher PB. Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons. Cancer Immunol Immunother 1992;35(5):315-324.
Mercer WE. Cell cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Expr 1992;2(3):251-263.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69(7):1237-1245.
Su ZZ, Olsson CA, Zimmer SG, Fisher PB. Transfer of a dominant-acting tumor-inducing oncogene from human prostatic carcinoma cells to cloned rat embryo fibroblast cells by DNA-transfection. Anticancer Res 1992;12(2):297-304.
Abdollahi A, Lord KA, Hoffman-Liebermann B, Liebermann DA. Sequence and expression of a cDNA encoding MyD118: a novel myeloid differentiation primary response gene induced by multiple cytokines. Oncogene 1991;6(1):165-167.
Bishop JM. Molecular themes in oncogenesis. Cell 1991;64(2):235-248.
Hara E, Kato T, Nakada S, Sekiya S, Oda K. Subtractive cDNA cloning using oligo(dT)30-latex and PCR: isolation of cDNA clones specific to undifferentiated human embryonal carcinoma cells. Nucleic Acids Res 1991;19(25):7097-7104.
Herfort MR, Garber AT (1991). Simple and efficient subtractive hybridization screening. Biotechniques 19
Baker & Botts L.L.P.
Marschel Ardin
The Trustees of Columbia University in the City of New York
LandOfFree
Methods of treating various cancers using melanoma... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating various cancers using melanoma..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating various cancers using melanoma... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505608